CAJ | 학술논문

目的：探讨阿托伐他汀对动脉粥样硬化早期血管保护的作用。方法：选择具有2个以上心血管危险因素而没有动脉粥样硬化斑块的患者120例，随机均分为4组，均予以控制心血管危险因素治疗。其中对照组不使用阿托伐他汀干预，5mg 组、10mg 组、20mg 组予以不同剂量的阿托伐他汀干预。随访6月，观察血栓素 B2（TXB2）、6-酮-前列腺素 F1α（6-Keto-PGF1α）、臂踝脉搏波传导速度（baPWV）、踝臂指数（ABI）以及颈动脉内膜中层厚度（IMT）的变化。结果：4组治疗前后 ABI 和 IMT 无显著变化（P 均＞0.05）。与基线比较，治疗后对照组和5mg组 TXB2、baPWV 水平显著升高，6-Keto-PGF1α水平显著降低；与之相反，10mg 组、20mg 组 TXB2、baPWV 水平显著降低，6-Keto-PGF1α水平显著升高（P ＜0.05～＜0.01）。治疗6个月后与对照组和5mg 组比较，10mg 组、20mg 组的 TXB2[（148.3±29.2）pg/ml，，（142.3±30.6）pg/ml 比（111.5±22.8）pg/ml，（104.9±17.4）pg/ml]、baPWV [（1621.1±136.1）cm/s，（1597.7±125.3）cm/s 比（1232.9±132.3）cm/s，（1178.2±155.1）cm/s]水平显著降低，6-Keto-PGF1α[（104.7±66.1）pg/ml，（102.2±70.3）pg/ml 比（132.8±48.3）pg/ml，（139.1±66.3）pg/ml]水平显著升高（P ＜0.05～＜0.01）。结论：阿托伐他汀对动脉粥样硬化早期血管有保护的作用，10mg 阿托伐他汀可能是血管保护的最低有效剂量。
목적：탐토아탁벌타정대동맥죽양경화조기혈관보호적작용。방법：선택구유2개이상심혈관위험인소이몰유동맥죽양경화반괴적환자120례，수궤균분위4조，균여이공제심혈관위험인소치료。기중대조조불사용아탁벌타정간예，5mg 조、10mg 조、20mg 조여이불동제량적아탁벌타정간예。수방6월，관찰혈전소 B2（TXB2）、6-동-전렬선소 F1α（6-Keto-PGF1α）、비과맥박파전도속도（baPWV）、과비지수（ABI）이급경동맥내막중층후도（IMT）적변화。결과：4조치료전후 ABI 화 IMT 무현저변화（P 균＞0.05）。여기선비교，치료후대조조화5mg조 TXB2、baPWV 수평현저승고，6-Keto-PGF1α수평현저강저；여지상반，10mg 조、20mg 조 TXB2、baPWV 수평현저강저，6-Keto-PGF1α수평현저승고（P ＜0.05～＜0.01）。치료6개월후여대조조화5mg 조비교，10mg 조、20mg 조적 TXB2[（148.3±29.2）pg/ml，，（142.3±30.6）pg/ml 비（111.5±22.8）pg/ml，（104.9±17.4）pg/ml]、baPWV [（1621.1±136.1）cm/s，（1597.7±125.3）cm/s 비（1232.9±132.3）cm/s，（1178.2±155.1）cm/s]수평현저강저，6-Keto-PGF1α[（104.7±66.1）pg/ml，（102.2±70.3）pg/ml 비（132.8±48.3）pg/ml，（139.1±66.3）pg/ml]수평현저승고（P ＜0.05～＜0.01）。결론：아탁벌타정대동맥죽양경화조기혈관유보호적작용，10mg 아탁벌타정가능시혈관보호적최저유효제량。
Objective:To explore protective effect of atorvastatin on blood vessels in early stage of atherosclerosis (AS).Methods:A total of 120 patients without AS plaques,who had >2 cardiovascular risk factors and received control cardiovascular risk factors therapy,were randomly divided into four groups:control group (did not receive atorvastatin),atorvastatin 5mg group,10mg group and 20mg group (received corresponding dose of atorvastatin). All patients were followed up for six months,changes of thromboxane B2 (TXB2),6-Keto-prostaglandin F1α (6-Keto-PGF1α),brachial-ankle pulse wave velocity (baPWV),ankle brachial index (ABI)and intima-media thickness (IMT)were observed.Results:There were no significant changes in ABI and IMT between before and after treat-ment among four groups (P >0.05 all).Compared with baseline,TXB2、baPWV levels significantly rose,6-Keto-PGF1αlevel significantly decreased after treatment in control group and 5mg group;in contrast,TXB2、baPWV lev-els significantly decreased,6-Keto-PGF1αlevel significantly rose after treatment in 10mg group and 20mg group(P <0.05~ < 0.01).After treatment six-month,compared with control group and 5mg group,the TXB2 [(148.3 ± 29.2)pg/ml,(142.3±30.6)pg/ml vs.(111.5±22.8)pg/ml,(104.9 ± 17.4)pg/ml]、baPWV[(1621.1 ± 136.1) cm/s,(1597.7±125.3)cm/s vs.(1232.9±132.3)cm/s,(1178.2±155.1)cm/s]levels significantly decreased,6-Keto-PGF1α[(104.7±66.1)pg/ml,(102.2±70.3)pg/ml vs.(132.8±48.3)pg/ml,(139.1±66.3)pg/ml]level significantly rose(P <0.05~<0.01)in 10 mg group and 20 mg group.Conclusion:Atorvastatin has protective effect on blood vessels in early stage of atherosclerosis,and 10mg atorvastatin may be the minimum effective dosage to protect blood vessels.